Patents by Inventor Robert Craig MELLING

Robert Craig MELLING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHOLINATE OF 2-(1-CYCLOBUTYL-1H-PYRAZOL-4-YL)-5-[([{1-[2-FLUORO-4-(TRIFLUOROMETHYL)-PHENYL]CYCLOPROPYL}CARBONYL)AMINO]BENZOIC ACID
    Publication number: 20250282734
    Abstract: The present invention relates to the choline salt (cholinate) of 2-(1-cyclobutyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)-phenyl]cyclopropyl}carbonyl)amino]benzoic acid. In particular, the invention relates to the compound according to formula (II): or a tautomer, solvate or hydrate thereof, as well as to medical uses of the cholinate according to the invention.
    Type: Application
    Filed: July 4, 2022
    Publication date: September 11, 2025
    Inventors: Stefan BÄURLE, Hans-Georg LERCHEN, Britta OLENIK, Guillaume LEVILAIN, Birgit KEIL, Sylvia DWORACEK, Antje ROTTMANN, Andrea ROTGERI, Robert Craig MELLING
  • 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR
    Publication number: 20250002481
    Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4 -yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.
    Type: Application
    Filed: May 31, 2024
    Publication date: January 2, 2025
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Michael READER, Nicola Elizabeth WILSHER, Mark Henry SAUNDERS, Paul Anthony BAGULEY, Colin Thomas LINDLEY, Robert Craig MELLING, Bozena Ewa ADAMCZYK, Mirka SCARATI
  • 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor
    Patent number: 12030873
    Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: July 9, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Paul Anthony Baguley, Colin Thomas Lindley, Robert Craig Melling
  • 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR
    Publication number: 20220169638
    Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.
    Type: Application
    Filed: September 1, 2021
    Publication date: June 2, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Michael READER, Nicola Elizabeth WILSHER, Mark Henry SAUNDERS, Paul Anthony BAGULEY, Colin Thomas LINDLEY, Robert Craig MELLING, Bozena Ewa ADAMCZYK, Mirka SCARATI
  • 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor
    Patent number: 11142518
    Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: October 12, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Michael Reader, Nicola Elizabeth Wilsher, Mark Henry Saunders, Paul Anthony Baguley, Colin Thomas Lindley, Robert Craig Melling, Bozena Ewa Adamczyk, Mirka Scarati
  • 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR
    Publication number: 20210101889
    Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 8, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Michael READER, Nicola Elizabeth WILSHER, Mark Henry SAUNDERS, Paul Anthony BAGULEY, Colin Thomas LINDLEY, Robert Craig MELLING, Bozena Ewa ADAMCZYK, Mirka SCARATI